Loading
companiesCompany
Digistain
Digistain shines infrared light through a breast tumour slide and reads its chemical fingerprint to score how likely the cancer is to return, giving a result in a day rather than weeks and at a fraction of the cost of genomic tests.
Overview
Digistain, an Imperial College London spin-out, measures the mid-infrared spectrum of a standard tumour section and applies an algorithm to produce a risk score for early breast cancer that is intended to guide chemotherapy decisions, an alternative to centralised genomic recurrence tests. The company cites a UK government-commissioned study showing clinical performance comparable to the market leader, and reports use with reimbursement at some cancer centres; it is supported by the NHS, YC and the European Investment Bank per its profile. Prospective outcome data are still limited.
Headquarters
London, GB
Funding
All startupsStartupYC S21
Investors
Type
Stage
Startup · Y Combinator Summer 2021
Website
Similar pages
- CompanyHistoWiz
Shares Y Combinator, Digital pathology & AI, Histopathology & immunohistochemistry and the tag yc.
- CompanyX-Zell
Shares Y Combinator, Digital pathology & AI and the tag yc.
- CompanySignatur Biosciences
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyClear Gene
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyNearWave
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.